BUHLMANN Citations Archives - Page 11 of 14 - Buhlmann Diagnostics Corp

Category: BUHLMANN Citations

A number of the publications in the citation list describe applications that are outside of product claims thus they should be used for information only.

Fcγ Receptor IIIA Genotype is Associated with Rituximab Response in Anti-Myelin-Associated Glycoprotein Neuropathy

Anti-MAG Autoantibodies ELISA Citation: Stork AC et al.; Fcγ receptor IIIA genotype is associated with rituximab response in anti-myelin-associated glycoprotein neuropathy. J Neurol Neurosurg Psychiatry. 2014 Aug;85(8): 918-20.PMID:24487381 Read Citation Anti-MAG Autoantibodies ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US. Health Canada License: 89118
Continue Reading

Long-term Efficacy of Rituximab in IgM Anti-Myelin-Associated Glycoprotein Neuropathy: RIMAG Follow-up Study; Journal of the Peripheral Nervous System

Anti-MAG Autoantibodies ELISA Citation: Ferfoglia R I et al.; Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study; Journal of the Peripheral Nervous System 21:10–14 (2016)PMID:26748872 Read Citation Anti-MAG Autoantibodies ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US. Health Canada License: 89118
Continue Reading

Classical and Lectin Complement Pathway Activity in Polyneuropathy Associated with IgM Monoclonal Gammopathy

Anti-MAG Autoantibodies ELISA Citations: Stork AC et al.; Classical and lectin complement pathway activity in polyneuropathy associated with IgM monoclonal gammopathy. J Neuroimmunol. 2016 Jan 15; 290:76-9. PMID:26711574 Read Citation Anti-MAG Autoantibodies ELISA is for Research Use Only.  Not for use in diagnostic procedures in the US. Health Canada License: 89118
Continue Reading

Anti-ganglioside Antibodies were not Detected in Human Subjects Infected with or Vaccinated Against 2009 Pandemic Influenza A (H1N1) Virus

Anti-GM1 Autoantibodies ELISA Citation: Lei T et al. Anti-ganglioside antibodies were not detected in human subjects infected with or vaccinated against 2009 pandemic influenza A (H1N1) virus. Vaccine. 2012 Mar 30; 30(16):2605-10.PMID:22342549 Highlight from this Publication "Anti-ganglioside antibodies, which might be associated with the development of GBS, were previously reported to be induced in mice
Continue Reading

The Presence of Mycoplasma Pneumoniae Infection and GM1 Ganglioside Antibodies in Guillain-Barré Syndrome

BÜHLMANN GanglioCombi ELISA Citation: Sharma MB et al.: The presence of Mycoplasma pneumoniae infection and GM1 ganglioside antibodies in Guillain-Barré syndrome. J Infect Dev Ctries. 2011 Jul 4; 5(6):459-64. PMID:21727645.   Highlight from this Publication "Significant difference in levels of anti GM1 ganglioside antibodies (IgG & IgM) was seen between GBS patients and non-neurological controls, highlighting
Continue Reading

Anti-Ganglioside Antibodies in Amyotrophic Lateral Sclerosis Revisited

BÜHLMANN GanglioCombi® MAG ELISA Citation Kollewe K et al.; Anti-ganglioside antibodies in amyotrophic lateral sclerosis revisited. PLoS One. 2015 Apr 14; 10(4):e0125339.     Highlight from this Publication "In the present study, we describe for the first time the utilization of a state of the art-ELISA assay to obtain reliable data on the occurrence of IgG
Continue Reading

Fecal Calprotectin in Healthy Children Aged 1-4 Years

BÜHLMANN fCAL® ELISA Citation: Zhu, Q,Feng Li, Junli Wang, Lixiao Shen, Xiaoyang Sheng. Fecal Calprotectin in Healthy Children Aged 1-4 Years, PLOS ONE. 2016. http://dx.doi.org/10.1371/journal.pone.0150725.

Highlight from this Publication:

“Children aged from 1 to 4 years old have lower FC concentrations compared with healthy infants (<1years), and higher FC concentrations when comparing with children older than 4 years and adults.”
Continue Reading

Comparison of Three Tests for Faecal Calprotectin in Children and Young Adults: a Retrospective Monocentric Study

BÜHLMANN fCAL® ELISA Citation: Prell, C, Nagel D, Freudenberg H, Schwarzer A, Koletzko S. Comparison of three tests for faecal calprotectin in children and young adults: a retrospective monocentric study, BMJ Open. 2014;4:e004558 doi:10.1136/bmjopen-2013-004558.

Highlights from this Publication

“In conclusion, measurement of FC in paediatric patients with unspecific symptoms is very helpful in order to avoid invasive procedure.”
Continue Reading

Are We Exposing Patients with a Mildly Elevated Faecal Calprotectin to Unnecessary Investigations?

BÜHLMANN fCAL®ELISA Citation: Seenan, JP, Thomson, Rankin K, Smith K, Gaya DR. Are we exposing patients with a mildly elevated faecal calprotectin to unnecessary investigations? Gastroenterology. 2014 Frontline Gastroenterol doi:10.1136/flgastro-2014-100467.

Highlight from this Publication:

“...we propose an alternative diagnostic approach of repeating the FC after 6-8 weeks in patients with values of 100-200 µg/g.”
Continue Reading

Fecal Calprotectin in Inflammatory Bowel Disease

BÜHLMANN fCAL® ELISA Citation Walsham and Sherwood. Fecal calprotectin in inflammatory bowel disease, Clinical and Experimental Gastroenterology. 2016; 9: 21–29.Published online 2016 Jan 28. doi: 10.2147/CEG.S51902

Highlight from this Publication

“The choice of a cutoff will depend on whether sensitivity or specificity is considered to be the most important and needs to be made taking into consideration the clinical features of an individual patient.”
Continue Reading